Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
The lactam emerged as lead candidate due
2024-08-01

The lactam (6) emerged as lead candidate due to its high selectivity, outstanding potency (against ALK or in clinically known ALK mutants), low in vitro clearance, and low efflux potential. The lactam (6) was selected for further profiling against the resistant ALK mutants. Preclinical rat pharmacok
-
moclobemide mg It is well accepted that
2024-08-01

It is well accepted that PKA is a key enzyme activated at the beginning of the capacitation process [69]. As mentioned above phosphorylation/inactivation of cofilin in sperm is a PKA dependent process [58]. We could not see any change in cofilin phosphorylation level by adding the PKA activator 8Br-
-
br ACK signaling partners ACK interacts with and tyrosine
2024-08-01

ACK1 signaling partners ACK1 interacts with and tyrosine phosphorylates many cellular proteins regulating critical cellular processes [11]. While ACK1 shares common intracellular effectors such as AKT with other signaling pathways, it imparts specificity to signaling by phosphorylating effectors
-
L-Cysteinesulfinic acid sale An alternative to the agonist o
2024-08-01

An alternative to the agonist or antagonist potential in drug discovery is the positive allosteric modulator (PAM) approach, which can augment the normal processes of neurotransmission as opposed to directly replacing or antagonizing them. PAMs are thought to bind to sites that are distinct from the
-
However although in vitro studies in heterologous
2024-07-31

However, although in vitro studies in heterologous systems have provided very important indications of potential novel pharmacology, the studies with endogenous receptors in native tissues are essential to provide evidence for GPCR heteromerization in vivo and to confirm its physiological relevance.
-
br Introduction Human esophageal carcinoma is one
2024-07-31

Introduction Human esophageal carcinoma is one of the most frequently diagnosed cancers, ranked as the eighth leading causes of cancer-related mortality worldwide. Esophagus squamous cell carcinoma (ESCC) is the most common histological type of esophageal carcinomas, especially with a higher inci
-
Lower LDL C mediated by variants in the
2024-07-31

Lower LDL-C mediated by variants in the ACL gene is causally associated with the risk of cardiovascular events. Because, genetic variants that mimic the effect of an ACL inhibitor have the same effect on the risk of cardiovascular events per unit change in LDL-C as variants that mimic the effect of
-
The potent inhibition of aromatase by ziram indeed caused th
2024-07-31

The potent inhibition of aromatase by ziram indeed caused the lower estradiol production in JEG-3 cells (Fig. 4), confirming that ziram can penetrate the cell membrane to get into the cells to act. However, the treatment of ziram did not lower progesterone production in JEG-3 cells (Fig. 4), indicat
-
In summary present evidence suggests
2024-07-31

In summary, present evidence suggests that antimicrobial therapy for intra-abdominal sepsis can be shortened in patients exhibiting a clinical response to treatment. Hence, clinicians should use the resolution of clinical signs of infection as a guide to determine when during the 4–7-day window anti
-
br Other Strategies for HIF Inhibition NSC is another HIF
2024-07-31

Other Strategies for HIF-α Inhibition NSC-644221 is another HIF-α inhibitor acting at the translational level, independently of proteasomal degradation and VHL status, and is devoid of DNA damage-inducing properties [70]. NSC-644221 arrests ll 37 mg in G2–M through a cell type-specific Topo-2-de
-
br Material and methods br Results br Discussion Nimodipine
2024-07-31

Material and methods Results Discussion Nimodipine administration inhibited the level of AMP-activated protein kinase (AMPK) phosphorylation, a sensor of cellular energy status that directs metabolic Artemisinine to support cellular growth and survival. CCH influences the oxygen and glucose
-
br Competing interests br Acknowledgments This research was
2024-07-31

Competing interests Acknowledgments This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2014R1A4A1071040). Introduction Mitochondria occupy an important position as mediators of
-
br Possible complementarity of trimming pathways Determining
2024-07-31

Possible complementarity of trimming pathways Determining the exact pathway for the generation or destruction of MHCI peptide ligands by ERAP1 is important for our understanding of the shaping of the immunopeptidome and for designing inhibitors that can manipulate it. It is also possible however
-
br Glioblastoma GBM is the highest grade glioma
2024-07-30

Glioblastoma GBM is the highest-grade glioma (Grade IV) according to WHO classification and belongs to the most malignant form of pgp inhibitors tumor. It is an incurable disease despite the use of aggressive treatments that include surgery and radiotherapy, usually in combination with chemother
-
br Acknowledgements Dr Paul J Gasser is supported by the
2024-07-30

Acknowledgements Dr. Paul J. Gasser is supported by the National Institutes of Health (grant number R01DA032895), and the Charles E. Kubly Mental Health Research Center. Dr. Christopher A. Lowry is supported by the National Institutes of Health (grant number R21 MH116263), the Department of the N
16253 records 114/1084 page Previous Next First page 上5页 111112113114115 下5页 Last page